-
-
Overview
-
Please contact us at for specific academic pricing.
Background
MLCK inhibitor peptide 18 is a cell-permeable inhibitor of MLCK (IC50 = 50 nM), with 4000-fold selectivity for MLCK over another closely related calmodulin (CaM)-regulated protein kinase, CaM-dependent kinase II (CaMPKII). MLCK inhibitor peptide 18 can cross cell membrane, and regulate paracellular permeability by reducing intracellular MLC phosphorylation, with the potential to restore barrier function in intestinal disease states. In addition, MLCK inhibitor peptide 18 can also inhibit chromosome-mediated cortical reorganization in mouse oocytes, as well as complement receptor-3 (CR3) mediated phagocytosis of C3bi-opsonized zymosan by mouse microglia.
1. Lukas TJ, Mirzoeva S, Slomczynska U, et al. Identification of novel classes of protein kinase inhibitors using combinatorial peptide chemistry based on functional genomics knowledge. Journal of Medicinal Chemistry, 1999, 42(5): 910-919.
2. Zolotarevsky Y, Hecht G, Koutsouris A, et al. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology, 2002, 123(1): 163-172.
3. Deng M, Williams CJ, Schultz RM. Role of MAP kinase and myosin light chain kinase in chromosome-induced development of mouse egg polarity. Developmental Biology, 2005, 278(2): 358-366.
4. Gitik M, Reichert F, Rotshenker S. Cytoskeleton plays a dual role of activation and inhibition in myelin and zymosan phagocytosis by microglia. The FASEB Journal, 2010, 24(7): 2211-2221.
-
- Properties
-
Overview